Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | FAAH | O00519 | 17/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | CNR2 | P34972 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010545 | 0.87 | CYP3A4 (0.72) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1011027 | 0.87 | FAAH (0.75) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1010836 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1009780 | 0.85 | CYP3A4 (0.81) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1011544 | 0.85 | FAAH (0.75) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1010533 | 0.85 | CYP3A4 (0.81) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1009288 | 0.85 | CYP3A4 (0.85) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1009439 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1010232 | 0.84 | CYP3A4 (0.78) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1010898 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2D6FAAHGABRA1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | claimed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | claimed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | claimed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | CYP3A4 303/4885CYP2D6 292/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.